Core Insights - Ardelyx, Inc. (NASDAQ:ARDX) is recognized as a fast-growing small-cap stock, with analysts providing positive ratings and price targets [1][2][3] Financial Performance - For fiscal Q3 2025, Ardelyx reported revenue of $110.33 million, reflecting a year-over-year growth of 12.3%, exceeding estimates by $9.78 million [2] - The company's EPS was $0.00, surpassing estimates by $0.07 [2] - Revenue growth was significantly driven by a 92% year-over-year increase in IBSRELA revenue, which reached $78.2 million, exceeding estimates by $7 million [2] Product Performance - The strong performance of IBSRELA is attributed to sustained demand from IBS-C patients for a differentiated treatment option [2] - Management has raised the revenue guidance for IBSRELA, expecting it to be between $270 million and $275 million for 2025 [2] Analyst Ratings - Julian Harrison from BTIG reiterated a Buy rating on Ardelyx with a price target of $14 [1] - Allison Bratzel from Piper Sandler raised the price target from $9 to $10 while maintaining a Hold rating [1][3] - Bratzel noted that the growth in IBSRELA demonstrates the strength of the company's sales force [3]